SBIR/STTR Research Award

Development of a Gene and Oligonucleotide Delivery System

Award identifier 1cd2d27d0ecd625bd2b5ce304f87fb5765baf9dfbc1cdce2205ed28c8e1c7577Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$322,946

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
MOLECULAR EXPRESS, INC
Proposal award date
2015-09-01
Contract end date
2016-08-31
UEI
R1JMHFESEKD5
Solicitation number
PA14-308
Topic code
NCATS

Research abstract

DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs These delivery agents are prepared by the in vitro self assembly of pure G MEDS and pure viral capsid protein CP into virus like nanoparticles particles VLPs The capsid protects the contents yet as we have demonstrated is capable of giving up its contents in the cytoplasm of mammalian cells The particles which are highly mono disperse are then enveloped by lipid bilayers that can suppress the immunogenicity of the VLPs and are capable of being functionalized for targeting and uptake by mammalian cells of interest In preliminary experiments we have demonstrated our ability to prepare EVLPs using the CP of the cowpea chlorotic mottle virus and a model antisense ODN for vascular endothelial growth factor VEGF a protein over expressed in many cancer cells to stimulate angiogenesis a facilitate tumor survival under low oxygen conditions We propose to optimize the assembly and to functionalize the lipid bilayers with epidermal growth factor EGF which binds the EGF receptor that is over expressed on cancer cells especially those of breast cancer The effectiveness of the EVLP will be demonstrated by assaying the reduction in the secretion of VEGF in cultured breast cancer cells PUBLIC HEALTH RELEVANCE The development of the proposed system for delivering genetic medicines such as genes and oligonucleotides would be an important medical advance Its development would facilitate the targeted delivery of genetic medicines to specific cells tissues and organs thus enabling the development of healthcare products which will exert a significant impact on the practice of medicine

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.